Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Inclusion Criteria: * Written informed consent * Documented HIV infection * Age 18 - 70 years * HBV DNA \> 10E6 copies/ml * ALT \< 10 x ULN (upper limit of normal) * Creatinine \<= 2.0mg/dl * Platelet count \>= 50,000/mm3 * HIV-1 therapy naive * No prior exposure to anti-HBV agents Exclusion Criteria: * Hepatitis C viral RNA (CV-RNA) positive or Anti-hepatitis A virus immunoglobulin M (HAV IgM) positive * Acute hepatitis (serum ALT \> 1000 U/L) * Prior LAM, TDF, or adefovir dipivoxil (ADV) therapy * Active opportunistic infection * Pregnancy or lactation * Other chronic liver disease * Concurrent malignancy requiring cytotoxic chemotherapy * Decompensated or Child's C cirrhosis * Alfa-fetoprotein (AFP) \> 3X ULN (unless negative computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\] within 3 months of entry date)